- A disease of all the tissues of the diarthrodial synovial joint (note: freely moveable joints, such as the knee and shoulder)
- Disorder of diverse aetiologies (note: origins)
- Can affect the small and the large joints; either singly (localized) or in combination (generalized)
|Knee||Three or more areas|
|Other single sites|
- Can be attributed to wear and tear at the joints (i.e. degenerative joint disease)
- Genetic influence
- Body mass index (BMI) correlates with the presence of osteoarthritis (OA)
- Link between obesity and osteoarthitis of the knee is more consistent in women with the biggest prevalence in knee osteoarthritis
- A study in middle-aged women it was suggested that the risk of knee osteoarthritis increases by 35% for every 5kg of body weight gain
- Below the age of 45, osteoarthritis (OA) is more common in men and it sometimes involves two joints
- Increasing age – at least up to the age of 70
- Injury to the joint (post-traumatic)
- Joint hyper-mobility or instability
- Prolonged occupational or sports stress
- Abnormalities of the biomaterials of the joint, usually the articular cartilage
- Abnormalities of the biomechanics of the joint, usually due to the abnormal joint structure, resulting in abnormalities in the distribution of loading forces across the joint
At the diseased joint when moving or after a period of rest (first mobility)
- The greatest incidence of OA occurs at 45 years, when OA develops in the interphalangeal joints and the carpometacarpal (CMC) joint. This is then followed by knee joint and hip.
- The prevalence of OA of the knee among adults aged 55 to 74 years is greater in women than in men
Hyaluronic Acid (HA) falls under the category of viscosupplementation.
Hyaluronic acid is found in the synovial joint and in OA patients, the level of HA is greatly diminished in molecular weight and concentration.
Viscosupplementation is the term used to indicate the administration of hyaluronic acid (HA) into the synovial fluid to help regain the natural balance which has been lost in an OA joint.
RenehaVis™ is a product containing 2 different HAs in different concentrations for knee osteoarthitis treatment. RenehaVis™ is an innovative new product which has shown in a clinical trial to help patients experience less pain faster and better than other HA products.
RenehaVis™ can be used for Grades 1, 2A and 2B knee OA.
In our clinical trial, RenehaVis™ has shown to help patients by the 2nd injection, instead of the usual 3 injections required. RenehaVis™ patients also had a better global satisfaction compared to the patients on other products.
Patients are usually asked to wait for a couple of hours before resuming regular activities, with a slow progression especially if effort is needed.
There has been no clinical evidence of the reformation of the cartilage layer found in the knee of OA patients. Although, it is proven that patients that use viscosupplementation may delay the progression of the disease.